AbbVie (ABBV) Total Non-Current Liabilities (2012 - 2026)

AbbVie (ABBV) has reported Total Non-Current Liabilities for 15 consecutive years, with $102.4 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Total Non-Current Liabilities fell 9.78% year-over-year to $102.4 billion; the TTM figure through Mar 2026 stood at $102.4 billion (down 9.78% YoY), while the FY2025 annual figure was $101.4 billion, down 10.66% from the prior year.
• Total Non-Current Liabilities advanced to $102.4 billion in Q1 2026 per ABBV's latest filing, from $101.4 billion in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $129.4 billion in Q1 2022 and bottomed at $101.4 billion in Q4 2025.
• Historically, Total Non-Current Liabilities has averaged $116.5 billion across 5 years, with a median of $116.6 billion in 2023.
• Annual changes were most pronounced in 2024 — Total Non-Current Liabilities increased 10.38% — and 2025, when it slipped 15.85%.
• AbbVie's Total Non-Current Liabilities stood at $122.4 billion in 2022, then decreased by 6.21% to $114.8 billion in 2023, then declined by 1.15% to $113.5 billion in 2024, then slipped by 10.66% to $101.4 billion in 2025, then increased by 0.95% to $102.4 billion in 2026.
• Business Quant data shows ABBV's Total Non-Current Liabilities at $102.4 billion in Q1 2026, $101.4 billion in Q4 2025, and $102.2 billion in Q3 2025.